#ESMO26将带来更多ADC + IO数据！
II期sacituzumab tirumotecan (sac-TMT) + pembrolizumab用于不适合顺铂治疗的mUC (n=40) #esmo26 #oncoalert
• ORR 68%，DCR 88%
• 中位DOR 19.4个月
• 中位PFS 11.2个月
• ≥3级TRAEs 63%
在TROP2/PD-L1各亚组中均观察到活性。疗效令人鼓舞，AE特征可管理。
缓解率和PFS与早期EV/P数据相近。
12 浏览 · 2 赞 · 1 转发 · 0 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：David H Aggen, MD PhD · x.com